Dexamethasone nanomedicines for COVID-19
Publication date
2020-08
Authors
Lammers, Twan
Sofias, Alexandros Marios
van der Meel, Roy
Schiffelers, Raymond M
Storm, G.
Tacke, Frank
Koschmieder, Steffen
Brümmendorf, Tim H
Kiessling, Fabian
Metselaar, Josbert M
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
taverne
Abstract
Nano-formulating dexamethasone, and administering it via intravenous injection or inhalation, may help to improve anti-COVID-19 treatment efficacy by targeting the potent corticosteroid drug to hyper-activated immune cells, by potentiating its anti-oedema activity and by exploiting its anti-fibrotic effects.
Keywords
Betacoronavirus/drug effects, COVID-19, Coronavirus Infections/drug therapy, Dexamethasone/therapeutic use, Humans, Nanomedicine, Pandemics, Pneumonia, Viral/drug therapy, SARS-CoV-2, Taverne
Citation
Lammers, T, Sofias, A M, van der Meel, R, Schiffelers, R, Storm, G, Tacke, F, Koschmieder, S, Brümmendorf, T H, Kiessling, F & Metselaar, J M 2020, 'Dexamethasone nanomedicines for COVID-19', Nature Nanotechnology, vol. 15, no. 8, pp. 622-624. https://doi.org/10.1038/s41565-020-0752-z